(Q43261449)

English

Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer

scientific article published on 14 October 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

phase III clinical trial

0 references

author name string

K N Syrigos

1

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

J Vansteenkiste

2

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

P Parikh

3

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

J von Pawel

4

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

C Manegold

5

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

R G Martins

6

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

L Simms

7

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

K P Sugarman

8

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

C Visseren-Grul

9

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

G V Scagliotti

10

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

publication date

14 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

556-561

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Prognostic factors in non-small cell lung cancer: a decade of progress

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

Smoking and lung cancer survival: the role of comorbidity and treatment.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

Lung cancer in never smokers--a different disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP392

21 January 2018

Identifiers

10.1093/ANNONC/MDP392

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43261449&oldid=2099071099"